clinical trial · NCT07369154
52-week Open Label Safety-Tolerability Study
SchizophreniaLB-102
brief summary
Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia
started
Apr 1, 2026
primary completion
Dec 1, 2028
completion
Apr 1, 2029
last updated
May 15, 2026
detailed description
Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia who are experiencing inadequate response or who are having issues with side effects, general tolerability, or overall effectiveness of their current antipsychotic medication and desire to change medications, or who have completed their participation in current LB-102 clinical studies
official title
A 52 Week, Open Label Safety and Tolerability Study of LB-102 in Adult Patients With Schizophrenia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol